EIDX News and Press, Eidos Therapeutics Inc. From 05/31/19

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

SAN FRANCISCO, May 07, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX),  today reported its financial results for the first quarter ended March 31, 2019 and provided an update on the company’s recent achievements. “The initiation of our Pha...

Catalyst Pharmaceuticals ( CPRX ) - As I'm writing this, the stock has lost 40% of its value in a single day after news came that the FDA approved Ruzurgi from Jacobus Pharma for LEMS (Lambert-Eaton myasthenic syndrome) patients age six to less than 17 years of age. This is the first app...

TTR amyloidosis or ATTR is a protein misfolding disease that has received a lot of attention over the last couple of years, with the approval of Alnylam’s ( ALNY ) first RNAi therapy Onpattro/patirisan in this indication. A number of other therapies are in late stages, with Pfizerȁ...

Eidos Therapeutics (NASDAQ: EIDX ): Q4 GAAP EPS of -$0.27  b eats by $0.01. More news on: Eidos Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SAN FRANCISCO, April 15, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the fourth quarter and full year ended December 31, 2018 and provided an update on the company’s recent achievements. “2018 marked...

BERWYN, Pa. , April 5, 2019 /PRNewswire/ --  RM LAW, P.C.  announces an investigation on behalf of Eidos Therapeutics, Inc. (NASDAQ: EIDX) ("Eidos Therapeutics" or the "Company") investors concerning the Company and its officers' possible violations of federal securities laws. ...

BOSTON, April 01, 2019 (GLOBE NEWSWIRE) -- Block & Leviton LLP ( www.blockesq.com ), one of the nation’s leading securities litigation firms representing investors nationwide, is investigating whether Eidos Therapeutics, Inc. (“Eidos” or the “Company”...

AG10 demonstrated equivalent, near-complete stabilization of TTR in wild-type and mutant subjects with TTR amyloid cardiomyopathy (ATTR-CM). AG10 treatment normalized serum TTR levels, a prognostic indicator of survival in ATTR-CM patients, in all mutant and wild-type subjects. AG...

SAN FRANCISCO, March 11, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics , Inc. (Eidos) (Nasdaq: EIDX ) today announced that management is scheduled to participate in a fireside chat regarding Eidos at the 31 st Annual ROTH Conference on Monday, March 18 th at 8:30 a.m. PDT in Orange Count...